Followers | 437 |
Posts | 42954 |
Boards Moderated | 2 |
Alias Born | 05/08/2006 |
Saturday, June 30, 2007 10:49:15 AM
RedChip Special Situation
Sunnylife Global, Inc. (SNYL.PK) reported recently that it has signed a joint venture agreement in Beijing, China with Kang He Biotechnological Group of Taiwan to assist Sunnylife in the development and financing of its World Friendship Hospitals in China and the “Garden of the Silver'’ assisted living care project in Boatou, Inner Mongolia.
Announcement of the joint venture was pending receipt by Kang He Biotechnological Group of approvals from the government of China to enter into this joint venture with Sunnylife Global, Inc.
Kang He Biotechnological Group is a company that focuses on the research and development of biological healthcare products and management of hospitals. For more than five years, Kang He has been successful in working with China’s healthcare industry and serving as a platform for legalizing Taiwan doctors to practice in China.
Sunnylife Global, Inc. has developed a Health Management System (HMS) in conjunction with the Chinese Government Authorities that will result in delivering superior quality health care management to its members.
The Company is in multiple joint venture agreements with the World Friendship Hospital Group to renovate and revitalize China’s older hospital facilities in order to meet the current International standard.
Sunnylife has developed the HMS to meet that standard and is planning to launch in the very near future. In addition, the Company has patented natural, environmentally safe and economically affordable products which it plans to introduce to Chinese consumers through seven different joint venture licensees in China.
"Please see the disclaimers on the QualityStocks.net website."
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM